Potential of biosurfactant as green pharmaceutical excipients for coating of microneedles: A mini review.

biosurfactants coating method excipients green pharmaceutical microneedles

Journal

AIMS microbiology
ISSN: 2471-1888
Titre abrégé: AIMS Microbiol
Pays: United States
ID NLM: 101697141

Informations de publication

Date de publication:
2024
Historique:
received: 14 05 2024
revised: 21 07 2024
accepted: 25 07 2024
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 2 9 2024
Statut: epublish

Résumé

Microneedles, a novel transdermal delivery system, were designed to improve drug delivery and address the challenges typically encountered with traditional injection practices. Discovering new and safe excipients for microneedle coating to replace existing chemical surfactants is advantageous to minimize their side effect on viable tissues. However, some side effects have also been observed for this application. The vast majority of studies suggest that using synthetic surfactants in microneedle formulations may result in skin irritation among other adverse effects. Hence, increasing knowledge about these components and their potential impacts on skin paves the way for finding preventive strategies to improve their application safety and potential efficacy. Biosurfactants, which are naturally produced surface active microbial products, are proposed as an alternative to synthetic surfactants with reduced side effects. The current review sheds light on potential and regulatory aspects of biosurfactants as safe excipients in the coating of microneedles.

Identifiants

pubmed: 39219752
doi: 10.3934/microbiol.2024028
pii: microbiol-10-03-028
pmc: PMC11362267
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

596-607

Informations de copyright

© 2024 the Author(s), licensee AIMS Press.

Déclaration de conflit d'intérêts

Conflict of interest: Ibrahim M. Banat is an editorial boardmember for AIMS Microbiology and was not involved inthe editorial review or the decision to publish this article. All authors declare that there are no competing interests. Author contributions: Marzieh Sajadi Bami, Payam Khazaeli, Mandana Ohadi, and Shayan Fakhraei Lahiji provided the general concept and wrote the manuscript. Marzieh Sajadi Bami and Gholamreza Dehghannoudeh prepared table and edited the text. Ibrahim M. Banat and Mandana Ohadi revised the manuscript and provided further editing and concepts. All authors have read and agreed to the published version of the manuscript.

Auteurs

Marzieh Sajadi Bami (MS)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Payam Khazaeli (P)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Shayan Fakhraei Lahiji (SF)

Department of Bioengineering, Biopharmaceutical Research Laboratory, Hanyang University, Seoul, South Korea.

Gholamreza Dehghannoudeh (G)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Ibrahim M Banat (IM)

School of Biomedical Sciences, Faculty of Life & Health Sciences, Ulster University, Coleraine BT52 1SA, Northern Ireland, UK.

Mandana Ohadi (M)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Classifications MeSH